Fludrocortisone
| Fludrocortisone | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 380.40 g/mol [1] |
| Appearance | Crystals [1] |
| Solubility | In water, 140 mg/L at 25 °C [1] |
| Predicted LogP | 1.7 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C21H29FO5 |
| IUPAC name | (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one |
| SMILES | C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O)F |
| InChI | InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1 |
| InChIKey | AAXVEMMRQDVLJB-BULBTXNYSA-N |
| CAS number | 127-31-1 |
| UNII | U0476M545B |
| PubChem CID | 31378 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 3.5 hours |
| Metabolism | Liver |
| Routes of administration | By mouth |
Fludrocortisone (also known as Astonin-H, Alflorone, Fluohydrisone, Fluorocortisol, Fluorocortisone, 9α-Fluorocortisol, Fludrocortone, Fluohydrocortisone, Fludrone or Fludronef).
Chemistry
Stereochemistry []
Fludrocortisone is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Fludrocortisone matches Lipinski's rule of five.Pharmacology
ATC Classification
- systemic hormonal preparations, excl. sex hormones and insulins (H)
- corticosteroids for systemic use (H02)
- corticosteroids for systemic use, plain (H02A)
- mineralocorticoids (H02AA)
- (H02AA02)
- fludrocortisone (H02AA02)
MeSH Classification
- anti-inflammatory agents (M0001333)
Mechanism of action []
The main endogenous mineralocorticoid, aldosterone, is produced in the zona glomerulosa of the adrenal cortex - it acts on mineralocorticoid receptors in the kidneys to increase sodium reabsorption and potassium excretion, which in turn helps to regulate plasma electrolyte composition and blood pressure. In conditions of adrenal insufficiency, such as Addison’s disease, aldosterone is not produced (or is produced in insufficient quantities) and must be replaced by exogenous mineralocorticoids such as fludrocortisone. Fludrocortisone binding to mineralocorticoid receptors causes alterations to DNA transcription and translation of proteins that result in an increased density of sodium channels on the apical side of renal tubule cells and an increased density of Na<sup>+</sup>-K<sup>+</sup>-ATPase on the basolateral side. These increases in receptor density result in increased plasma sodium concentrations, and thus increased blood pressure, as well as a decreased plasma potassium concentration. Fludrocortisone may also exert a direct effect on plasma sodium levels via action at the Na<sup>+</sup>-H<sup>+</sup> exchanger found in the apical membrane of renal tubule cells. Fludrocortisone also acts on glucocorticoid receptors, albeit with a much lower affinity - the glucocorticoid potency of fludrocortisone is approximately 5-10 times that of endogenous cortisol, whereas its mineralocorticoid potency is 200-400 times greater. [1]
Medical side effects []
76 side effects listed on drug labels in SIDER 4.1 (fludrocortisone).
- Abdominal distension
- Amenorrhoea
- Asthenia
- Infection
- Contusion
- Ecchymosis
- Oedema
- Oesophagitis
- Exophthalmos
- Multiple fractures
- Fracture
- Glaucoma
- Glycosuria
- Headache
- Cardiomegaly
- Cardiac failure congestive
- Haemorrhage
- Haemoglobin
- Hirsutism
- Hyperglycaemia
- Hypernatraemia
- Hypersensitivity
- Hypertension
- Muscle atrophy
- Neoplasm
- Osteoporosis
- Pancreatitis
- Optic neuritis
- Papilloedema
- Peptic ulcer
- Petechiae
- Benign intracranial hypertension
- Purpura
- Vascular purpura
- Convulsion
- Thrombophlebitis
- Urticaria
- Vertigo
- Injury
- Alkalosis hypokalaemic
- Mood swings
- Affect lability
- Osteonecrosis
- Cataract
- Glucose tolerance decreased
- Impaired healing
- Intracranial pressure increased
- Muscular weakness
- Skin striae
- Menstruation irregular
- Skin hyperpigmentation
- Dermatitis acneiform
- Myalgia
- Musculoskeletal discomfort
- Intraocular pressure increased
- Cataract subcapsular
- Increased insulin requirement
- Erythema
- Muscle mass
- Diabetes mellitus
- Spinal compression fracture
- Fluid retention
- Myopathy
- Glucose tolerance impaired
- Atrophy
- Lipoatrophy
- Anaphylactic shock
- Anaphylactoid reaction
- Rash maculo-papular
- Carbohydrate tolerance decreased
- Vasculitis necrotising
- Dermatitis atopic
- Hyperhidrosis
- Nitrogen balance negative
- Insomnia
- Oesophagitis ulcerative
Indications
- Addison's disease
- Adrenogenital syndrome
- Breast cancer
- Neoplasm malignant
- Orthostatic hypotension
- Secondary adrenocortical insufficiency
Legal status []
External links []
- Fludrocortisone (Wikipedia)
- Fludrocortisone (PubChem)
- Fludrocortisone (Wikidata)
- Fludrocortisone (DrugBank)
- Fludrocortisone (ChEMBL)
- Fludrocortisone (ChEBI)
- Fludrocortisone (Common Chemistry)
- Fludrocortisone (HMDB)
- Fludrocortisone (KEGG)
- Fludrocortisone (EPA DSSTox)
- Fludrocortisone (Effect Index)
- Fludrocortisone (UNII)
- Fludrocortisone (SIDER)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 31378, Fludrocortisone. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/31378
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Fludrocortisone. UNII: U0476M545B. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/U0476M545B
Florinef Acetate Product information. Health Canada. 14 August 1997. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=839
Florinef Product information. Health Canada. 31 December 2024. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19460
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 19:01:21 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 19:01:17 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 19:01:17 |
| gsrs | ok | 2026-11-20 19:01:18 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014825) | 2026-11-20 19:01:17 |
| kegg | ok | 2026-11-20 19:01:19 |
| pubchem | ok | 2026-11-20 19:01:17 |
| missing (no r/tripreports posts mention it) | 2026-11-20 19:01:17 | |
| sider | ok | 2026-11-20 19:01:17 |
| structure | ok | 2026-11-20 19:01:17 |
| wikipedia | ok | 2026-11-20 19:01:18 |